FDA OKs First Targeted Therapy for Subset of Patients With NSCLC ...Middle East

Medscape - News
There is now a specific treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations – amivantamab (Rybrevant). Medscape Medical News

Hence then, the article about fda oks first targeted therapy for subset of patients with nsclc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA OKs First Targeted Therapy for Subset of Patients With NSCLC )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News